Recycling of SLC38A1 to the plasma membrane by DSCR3 promotes acquired temozolomide resistance in glioblastoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-022-03964-2
Abstract: Glioblastoma multiforme (GBM) is a primary brain tumor with devastating prognosis. Although the O6-methylguanine-DNA methyltransferase (MGMT) leads to inherent temozolomide (TMZ) resistance, approximately half of GBMs were sufficient to confer acquired TMZ resistance, which express… read more here.
Keywords: deficient gbm; dscr3; resistance; mgmt deficient ... See more keywords
Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-20-0099
Abstract: PTEN deletion or mutation occurs in 30% to 60% of patients with glioblastoma (GBM) and is associated with poor prognosis. Efficacious therapy for this subgroup of patients is currently lacking. To identify potential target(s) to… read more here.
Keywords: gbm cells; synthetic vulnerability; pten deficient; targeting synthetic ... See more keywords